News

When bad news drops, investors have a tendency to sell first and ask questions later. Let's take a closer look at why Viking ...
Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...
The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...
We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...
Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...
Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.
In April 2025 , Northstrive Biosciences announced it received preliminary feedback from the FDA on its planned Type B pre-IND ...
Current health news highlights include Viking's weight-loss pill failing to meet financial expectations, European corporate ...
In the second quarter, attributable net income increased by 45 percent to 1.5 billion yuan from 1.067 billion yuan in the ...
Nasdaq futures dipped a further 0.4% after investors sold AI tech stocks yesterday, leading to a near-1.5% daily decline, though the index is still up 40% since April's low. Palantir ( PLTR -9.39%) ...